Compare VHI & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VHI | CABA |
|---|---|---|
| Founded | 1932 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 505.0M | 495.7M |
| IPO Year | 1994 | 2019 |
| Metric | VHI | CABA |
|---|---|---|
| Price | $18.62 | $3.35 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $12.00 | ★ $14.50 |
| AVG Volume (30 Days) | 15.9K | ★ 4.6M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ 0.85 | N/A |
| Revenue | ★ $2,077,000,000.00 | N/A |
| Revenue This Year | $33.32 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.98 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.44 | $1.82 |
| 52 Week High | $19.19 | $4.23 |
| Indicator | VHI | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 65.52 | 58.25 |
| Support Level | $12.35 | $2.58 |
| Resistance Level | $19.19 | $3.41 |
| Average True Range (ATR) | 0.92 | 0.24 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 79.57 | 55.49 |
Valhi Inc is a holding company that provides chemicals, security products, waste management systems, and real estate development and management services through its subsidiaries. It operates its business in three segments, which are Chemicals, Component Products, and Real Estate Management and Development. The company derives maximum revenue from the Chemicals segment, which produces and markets value-added titanium dioxide pigments (TiO2). TiO2 is used to impart whiteness, brightness, opacity, and durability to various products, including paints, plastics, paper, fibers, and ceramics. Geographically, the company generates maximum revenue from the United States and also has a presence in Germany, Canada, Norway, and Belgium.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.